Pull to refresh
Logo
Innovent's SYCUME meets primary endpoint in inactive thyroid eye disease trial

Innovent's SYCUME meets primary endpoint in inactive thyroid eye disease trial

New Capabilities

Phase 3 RESTORE-3 trial shows 60.4% proptosis response in inactive thyroid eye disease

3 days ago: RESTORE-3 meets primary endpoint in inactive TED

Overview

Updated 1 hour ago

Innovent Biologics said its drug SYCUME reduced eye protrusion in Chinese patients with inactive thyroid eye disease, meeting the primary endpoint of a Phase 3 trial. At week 24, 60.4% of treated patients hit the proptosis response threshold, versus 23.5% on placebo.

The result matters because inactive TED patients make up roughly two-thirds of the TED population, and evidence for IGF-1R antibodies has been built mostly in active disease. SYCUME is already approved in China for TED and entered the national reimbursement list in January 2026, so the new data could expand its reach.

Why it matters

If approved for inactive TED, SYCUME would give roughly two-thirds of China's thyroid eye disease patients a reimbursed treatment option.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

60.4%
Proptosis response rate at week 24 (SYCUME group)
60.4% of treated patients met the response threshold vs 23.5% on placebo.
-1.88 mm
LS mean change in proptosis from baseline
Treated patients averaged -1.88 mm reduction vs -0.88 mm on placebo.
116
Participants randomized
Randomized 2:1 to SYCUME or placebo in the RESTORE-3 trial.
36.9 pts
Treatment difference in response rate
Percentage-point gap between SYCUME and placebo groups (p=0.0003).

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Organizations Involved

Timeline

March 2025 October 2026

4 events Latest: 3 days ago
Tap a bar to jump to that date
  1. RESTORE-3 meets primary endpoint in inactive TED

    Latest Clinical Trial

    Innovent announces 60.4% proptosis response rate at week 24, versus 23.5% on placebo, with favorable safety.

  2. SYCUME added to China's National Reimbursement Drug List

    Policy

    The drug entered the NRDL, reducing out-of-pocket costs for patients compared with overseas alternatives.

  3. RESTORE-3 trial begins recruiting

    Clinical Trial

    Phase 3 study of IBI311 in inactive TED starts, with estimated enrollment of 111 per ClinicalTrials.gov.

  4. SYCUME approved by NMPA for thyroid eye disease

    Regulatory

    China's drug regulator approved SYCUME for TED, making it the first IGF-1R antibody approved in China.

Scenarios

1

NMPA expands SYCUME's indication to inactive TED

Likely Resolves by End of 2027

Discussed by: Industry analysts reading the RESTORE-3 results

The positive Phase 3 data gives Innovent the evidence to seek an expanded label covering inactive TED. The company has not announced a filing timetable, but the results align with TEPEZZA's data in the same population, and SYCUME is already reimbursed in China.

2

Full RESTORE-3 data published in a peer-reviewed journal

Likely Resolves by End of 2027

Discussed by: Innovent's announcement, which said complete data will be presented at conferences or published

The company said follow-up is ongoing and full data will be published. Publication would let clinicians and regulators assess the complete safety and efficacy profile, including the durability of proptosis reduction.

3

Follow-up data confirm durable proptosis reduction

Possible Resolves by End of 2027

Discussed by: Trial design, which includes a follow-up phase through about week 64

RESTORE-3 includes a follow-up period after the week 24 primary readout. If the proptosis reduction holds through follow-up, it would strengthen the case for treating inactive TED and support the expanded indication.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

January 2020

TEPEZZA's FDA approval (2020)

Horizon Therapeutics' teprotumumab (TEPEZZA) became the first drug approved for thyroid eye disease, ending a roughly 70-year stretch with no approved treatment. The FDA cleared it for active TED based on trials showing significant proptosis reduction.

Then

TEPEZZA became the standard of care for active TED in the US, with rapid uptake despite high cost.

Now

It validated IGF-1R blockade as a therapeutic mechanism in TED and set the efficacy benchmark that later drugs, including SYCUME, are measured against.

Why this matters now

SYCUME is the second IGF-1R antibody approved worldwide, and RESTORE-3's results were compared directly against TEPEZZA's data in inactive TED.

2020s

TEPEZZA studies in inactive TED (2020s)

Researchers tested teprotumumab in patients with inactive TED, where disease activity scores are low but proptosis persists. Response rates were consistent with those seen in active disease.

Then

The data suggested IGF-1R blockade works regardless of disease activity, opening the door for treating the larger inactive population.

Now

It established the precedent that inactive TED patients, who make up about two-thirds of the TED population, could benefit from the therapy.

Why this matters now

RESTORE-3 is the first Phase 3 trial in China to test this hypothesis in inactive TED, and its results align with TEPEZZA's.

Sources

(6)